Agouron will pursue anticancer agents AG3340 and AG2034 following termination of Thymitaq program.
Executive Summary
AGOURON ONCOLOGY PROGRAM WILL FOCUS ON AG3340 AND AG2034 following termination of clinical trials for its lead anticancer agent, the thymidylate synthase inhibitor Thymitaq, the company announced Dec. 2. Interim analyses of the two Phase II/III trials of Thymitaq, in head and neck cancer and liver cancer, did not reach statistical significance, the company said.